Ann: Sales Agreement Executed in High-value Pharmaceutical market, page-14

They need to utilize full plant capacity - for that they need major customers. Track record so far is very poor on that front - as I recall they announced they were 'learning' about some of their 'target' markets - seem they still in the classroom.

Cautiously optimistic but at this point it may be a tad too flattering - need customers testing to be realized in major contracts earning millions. How long will the latest cr stretch without major sales revenues??

The venturing into so called green concrete sounds like a great potential but apart from a couple on non binding MOU's not really material as yet.

Impressive research house valuations give a warm and fuzzy feeling but current sp is a far cry from any such figures but then easy to see it being due to current company earnings - or should that be due to lack of.

Hopefully there will be a turnaround soon. Management better be fast learners - it seems holders are paying the tuition fees - if the learning curve is too steep, the tuition fees may increase resulting in more dilution pls sir. AIMO